Nektar also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.
 

Products by Therapeutic Area Nektar
Discovered
Indication Phase view all Partner
CNS/Pain  
MOVANTIK™ (naloxegol) Opioid-induced constipation (OIC)
Phase 3 Completed - Filed in USA, EU and Canada
AstraZeneca
NKTR-119 Analgesic for pain
Preclinical
AstraZeneca
NKTR-181 Chronic pain
Phase 2 Completed
 
NKTR-171 Neuropathic pain
Phase 1
 
NKTR-192 Acute pain
Preclinical
 
NKTR-174 Neuropathic Pain
Preclinical
 
NKTR-196 Acute Pain
Preclinical
 
NKTR-195 Visceral Pain
Preclinical
 
Oncology  
Etirinotecan pegol (NKTR-102) Metastatic Breast Cancer
Phase 3
 
Etirinotecan pegol (NKTR-102) Platinum-Resistant Ovarian Cancer
Phase 2 Completed
 
Etirinotecan pegol (NKTR-102) Second-Line Colorectal Cancer
Phase 2 Completed
 
Etirinotecan pegol (NKTR-102) Bevacizumab (Avastin)-refractory high-grade glioma
Phase 2
Investigator Sponsored Trial
Etirinotecan pegol (NKTR-102) Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Investigator Sponsored Trial
Etirinotecan pegol (NKTR-102) Small Cell Lung Cancer (SCLC)
Phase 2
Investigator Sponsored Trial
Etirinotecan pegol (NKTR-102) GI and solid tumors
In combination with
5-FU

Phase 1 Completed
 
NKTR-214 Immuno-oncology
Preclinical
 
Anti-Infectives  
Amikacin Inhale (NKTR-061)
(BAY41-6551)
Gram-negative pneumonia
Phase 3
Bayer
Ciprofloxacin DPI
(BAY Q3939)
Non-cystic fibrosis bronchiectasis
Phase 3
Bayer
NKTR-223 Gram-negative infections
Preclinical
 
Hemophilia  
BAX 855 (full-length longer-acting rFVIII molecule) Hemophilia A
Phase 3
Baxter
Longer-acting therapeutic clotting proteins Hemophilia and bleeding disorders
Preclinical
Baxter
Endocrine/Metabolic  
NKTR-228 Renal Disease
Preclinical
 
Other Royalty-Bearing Licensing Partnerships  
Fovista®   Neovascular Age-related Macular Degeneration
Phase 3
ophthotech
Revolixys™   Acute Coronary Syndrome
Phase 3
Regado Biosciences
SEMPRANA™
(dihydroergotamine)
  Migraine
Phase 3 Completed - NDA filed
Allergan

* Movatik™ is a trademark of AstraZeneca; SEMPRANA™ is a trademark and Tempo® is a registered trademark of Allergan, Inc.; Fovista® is a registered trademark of Ophthotech Corporation; Revolixys™ is a trademark of Regado Biosciences.

MOVANTIK™ (naloxegol)

  • Internally discovered by Nektar
  • Phase 3 Studies Complete, filed in US, EU and Canada

    MOVANTIK is an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA) specifically designed for the treatment of opioid-induced constipation (OIC) in patients with chronic non-cancer pain. In the Phase 3 clinical studies, MOVANTIK was administered as a once-daily tablet and is designed to block the binding of opioids to the opioid receptors in the gastrointestinal (GI) tract without impacting the opioid receptors in the brain. MOVANTIK was designed using Nektar's proprietary oral, small molecule polymer conjugate technology.
  • NKTR-119 (Movantik fixed-dose combination product)

  • Invented by Nektar
  • Currently in research/preclinical

    NKTR-119 is an investigational drug candidate that is a co-formulation of Movantik (naloxegol) and an opioid analgesic. The product is in preclinical stages for the treatment of pain without the gastrointestinal side effects associated with traditional opioid therapies.
  • NKTR-181

  • Invented by Nektar
  • Currently in Phase 2 clinical trials for chronic pain

    NKTR-181 is a new oral opioid analgesic candidate in development for the treatment of chronic pain. It is designed to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies. NKTR-181 is a novel mu-opioid agonist created using Nektar's proprietary polymer conjugate technology and its differentiating properties are inherent to the design of its new molecular structure.
  • NKTR-171

  • Invented by Nektar
  • Currently in Phase 1 clinical studies

    NKTR-171 is a peripherally-restricted sodium channel blocker designed to treat neuropathic pain without the CNS side effects. The product was developed using Nektar's advanced polymer conjugate technology and is currently in Phase 1 clinical studies.
  • NKTR-174

  • Invented by Nektar
  • Currently in research

    NKTR-174 is Nektar Therapeutics' product candidate for the treatment of neuropathic pain. NKTR-174 is a novel dual-acting small molecule with mu opioid agonist/NMDA antagonist activity created using Nektar technology.
  • NKTR-192

  • Invented by Nektar
  • Currently in Preclinical Studies

    NKTR-192 is Nektar Therapeutics' product candidate for the treatment of moderate to severe acute pain. NKTR-192 is a novel mu-opioid analgesic created using Nektar's advanced polymer conjugation technology to slow drug entry into the central nervous system (CNS). By dramatically slowing the rate of drug entry into the CNS, NKTR-192 is intended to maintain opioid-like efficacy without the abuse potential associated with rapid-acting opioids.
  • NKTR-195

  • Invented by Nektar
  • Currently in research

    NKTR-195 is Nektar Therapeutics' product candidate for the treatment of visceral pain. NKTR-195 is an oral peripherally-acting kappa agonist created using Nektar's advanced polymer conjugation technology.
  • NKTR-196

  • Invented by Nektar
  • Currently in research

    NKTR-196 is Nektar Therapeutics' product candidate for the treatment of acute pain. NKTR-196 is a novel rapid onset oral opioid created using Nektar's advanced polymer conjugation technology and designed to have low abuse potential.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Currently in Phase 3 clinical trials in metastatic breast cancer
  • Long-acting topoisomerase I-inhibitor

    Etirinotecan pegol (NKTR-102) is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform. It is the first long-acting topoisomerase I-inhibitor with a non-overlapping mechanism of action with other agents used to treat breast cancer, which may mitigate potential cancer cross-resistance and reduce overlapping toxicities. In November 2012, NKTR-102 was designated a Fast Track development program by the U.S. FDA for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with ATC.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Phase 2 clinical trials in second-line colorectal cancer are complete
  • Long-acting topoisomerase I-inhibitor

    Etirinotecan pegol (NKTR-102) is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Phase 2 clinical trials in platinum-refractory ovarian cancer
         are complete
  • Long-acting topoisomerase I-inhibitor

    Etirinotecan pegol (NKTR-102) is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Currently being evaluated in Phase 2 investigator sponsored
         clinical trial in high-grade glioma
  • Long-acting topoisomerase I-inhibitor

    Etirinotecan pegol (NKTR-102) is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform. This Phase 2 study of etirinotecan pegol in patients with bevacizumab (Avastin)-refractory high-grade glioma is an investigator-sponsored trial being conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Currently being evaluated in Phase 2 investigator sponsored
         clinical trial in Non-Small Cell Lung Cancer (NSCLC)
  • Long-acting topoisomerase I-inhibitor

    Etirinotecan pegol (NKTR-102) is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform. This Phase 2 study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer (NSCLC) is an investigator-sponsored trial being conducted at Abramson Cancer Center of the University of Pennsylvania under the direction of Corey Langer, M.D., Professor of Oncology.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Currently being evaluated in Phase 2 investigator sponsored
         clinical trial in Small Cell Lung Cancer (SCLC)
  • Long-acting topoisomerase I-inhibitor

    Etirinotecan pegol (NKTR-102) is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform. This Phase 2 study of etirinotecan pegol as a second-line treatment in patients with relapsed or refractory small cell lung cancer (SCLC) is an investigator-sponsored trial being conducted at Roswell Park Cancer Institute (RPCI )under the direction of Alex Adjei, M.D., Ph.D., F.A.C.P., Senior Vice President for Clinical Research and Chair of the Department of Medicine at RPCI.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Currently in Phase 1 clinical trials in multiple tumor settings
  • Long-acting topoisomerase I-inhibitor

    Etirinotecan pegol (NKTR-102) is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform. The phase 1 study to assess the safety, pharmacokinetics and anti-tumor activity of NKTR-102 when given in combination with standard doses of 5-FU/leucovorin in patients with advanced cancer is now complete. Data from the study demonstrated that NKTR-102 can be safely combined with 5-FU/LV, and showed signs of clinical benefit including both objective responses and tumor marker reductions.
  • NKTR-214

  • Invented by Nektar
  • Currently in research/preclinical

    NKTR-214 is a drug candidate designed to kill tumors through stimulation of the immune system. The product was developed using Nektar's advanced polymer conjugate technology and is in early research.
  • Amikacin Inhale (NKTR-061)

  • Aerosolized antibiotic in both on and off ventilator setting

    Amikacin Inhale is a drug-device combination product, comprised of a specially formulated Amikacin Inhalation Solution with Nektar's Pulmonary Drug Delivery System (PDDS). It is being developed in partnership with Bayer HealthCare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia. The unique areosolization system, PDDS, was designed to achieve optimal lung penetration of the specially formulated Amikacin Inhale Solution, delivering antimicrobial agent directly to the site of infection in the lungs.
  • Ciprofloxacin DPI

    Under development by Bayer Healthcare, Ciprofloxacin Dry Powder for Inhalation (DPI) is an innovative drug-device combination being investigated in non-CF bronchiectasis (NCFB). The investigational product candidate is currently in Phase 3 clinical trials in patients with NCFB and features a small, hand-held inhaler for ease-of-use. Nektar is entitled to royalties on sales of Ciprofloxacin DPI upon commercialization.
    BAX 855 (full-length longer-acting rFVIII molecule)

    • BAX 855 is a full-length longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] - the most widely chosen rFVIII in the world. Through a collaboration with Nektar, BAX 855 leverages our proprietary PEGylation technology designed to extend the duration of activity of proteins. The technology has been shown to be safe and tolerable and is used in various approved treatments. A Phase 1 study showed the half-life of BAX 855 was approximately 1.5-fold higher compared to ADVATE and has the potential for less frequent dosing.

    • BAX 855 is Baxter's most advanced longer-acting candidate, and is in Phase 3 clinical development. The Phase 3 multicenter, open-label study of BAX 855 called PROLONG-ATE will assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding. The study completed enrollment of approximately 150 previously-treated adult patients with severe hemophilia A and Baxter expects to file an NDA with the FDA by the end of 2014. Information and enrollment details for the trial are available at www.clinicaltrials.gov or by emailing medinfo@baxter.com.
    NKTR-228

  • Invented by Nektar
  • Currently in research/preclinical

    NKTR-228 is a drug candidate designed to reduce parathyroid hormone levels in late stage renal disease patients. The product was developed using Nektar's advanced polymer conjugate technology and is in early research.
  • Fovista®

    Fovista® is an anti-platelet-derived growth factor (anti-PDGF) agent. Ophthotech is investigating Fovista® administered in combination with anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of neovascular age-related macular degeneration (wet AMD). In Phase 2 studies, Fovista® (1.5 mg) combination therapy showed superior efficacy with statistical significance over anti-VEGF monotherapy (standard of care) for wet AMD in a large (449 patients) superiority Phase 2b trial. Ophthotech has begun treating patients in two of three Phase 3 clinical trials for Fovista and plans to enroll 1,866 patients in its Phase 3 clinical trials. Two of the three Phase 3 clinical trials will evaluate the efficacy and safety of Fovista® administered in combination with Lucentis®; a third clinical trial will evaluate Fovista® administered in combination with each of Avastin® or Eylea®.

    Nektar has an exclusive worldwide license agreement with Ophthotech for Fovista. As part of the agreement, Nektar is entitled to development and commercial milestones and royalties on product sales of Fovista.
    Revolixys™

    The Revolixys Kit, is a two-component system comprising a Factor IXa inhibitor anticoagulant and its specific active control agent. Revolixys is being developed for use in patients suffering from acute coronary syndrome (ACS), including those who undergo coronary revascularization procedures, which include percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). These procedures put patients at risk for therapy-related bleeding complications. Revolixys is designed to increase therapeutic flexibility while reducing side effects and improving outcomes experienced by patients in this setting.

    The Revolixys Kit, is currently being evaluated in a Phase 3, PROBE design (Prospective, Randomized, Open-label, Blinded-Endpoint) superiority study (REGULATE-PCI) comparing the effects of Revolixys to bivalirudin in patients undergoing percutaneous coronary intervention (PCI) electively or for the treatment of unstable angina (UA) or non-ST elevated myocardial infarction (N-STEMI). REGULATE-PCI, if successful, will serve as the basis for product registration applications throughout the world.

    Nektar has an exclusive worldwide license agreement with Regado for Revolixys. As part of the agreement, Nektar is entitled to development and commercial milestones and royalties on product sales of Revolixys.
    SEMPRANA™ (dihydroergotamine)

    Under the terms of a license agreement between Nektar and Allergan, Inc., Nektar is entitled to receive royalties on the global sales of SEMPRANA for all indications. SEMPRANA is an orally inhaled version of dihydroergotamine (DHE), self-administered via Allergan's proprietary TEMPO® inhaler. DHE is available as an intravenous therapy which has been used in clinical settings for over 50 years to safely treat migraine. A New Drug Application (NDA) for SEMPRANA is currently being reviewed by the U.S. Food and Drug Administration (FDA).
    PEGPH20

    PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan (HA). Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is an indicator of poor prognosis. PEGPH20 has been shown to deplete this matrix component from the tumor that rapidly changes the tumor microenvironment and metabolism, which may render the tumor more vulnerable to therapy as well as inhibit tumor growth. PEGPH20 is currently being evaluated in a Phase 2 multicenter, randomized clinical trial of nab-paclitaxel and gemcitabine with and without PEGPH20 to assess the combination treatment effect as measured by ORR, PFS and OS. The study is expected to enroll approximately 124 patients with stage IV metastatic pancreatic cancer. A second Phase 2 study will evaluate PEGPH20 in combination with modified FOLFIRINOX in approximately 144 patients with advanced pancreatic cancer.

    Nektar has an exclusive worldwide license agreement with Halozyme for PEGPH20. As part of the agreement, Nektar is entitled to development and commercial milestones and royalties on product sales of PEGPH20.

     
     
    Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide